May 24, 2021 / 09:00PM GMT
Esther Rajavelu - UBS - Analyst
Good afternoon, everyone. Thank you for joining us at the UBS Virtual Healthcare Conference day one. I'm excited to have the Stoke Therapeutics management team here with us for a fireside chat. And I'm joined by Ed Kaye, CEO of Stoke. Ed, welcome, and thank you for making time for us today.
Ed Kaye - Stoke Therapeutics, Inc. - CEO & Director
Well, thank you. It's a pleasure to be here, and I look forward to talking about some of our programs.
Esther Rajavelu - UBS - Analyst
Great. So perhaps we can start off with a big picture question here as Stoke is positioned to initiate several trials in the US and EU for the lead program, and you also identified another target from the TANGO platform. So what is the vision here as you continue to make clinical progress across the platform and add to the pipeline?
Ed Kaye - Stoke Therapeutics, Inc. - CEO & Director
So, yes, our expectation and what we're building out is really a full-service
Stoke Therapeutics Inc at UBS Global Healthcare Virtual Conference Transcript
May 25, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers